Importance of appropriate patient selection for PARP inhibitors in prostate cancer
Atish D. Choudhury, MD, PhD, discusses the significance of optimizing patient selection when using PARP inhibitors for prostate cancer. Using these agents in patients unlikely to benefit adds unnecessary pill, toxicity, and financial burdens to the recipient, explains Choudhury. He notes the importance of finding biomarkers to facilitate appropriate patient selection.
Choudhury is a medical oncologist and clinical/translational investigator within the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and currently serves as Chair of the Gelb Center for Translational Research.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
